CORRADINI, PAOLO
CORRADINI, PAOLO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
2024 A. Chiappella, B. Casadei, P. Chiusolo, A. Di Rocco, S. Ljevar, M. Magni, P. Angelillo, A.M. Barbui, I. Cutini, A. Dodero, F. Bonifazi, M.C. Tisi, S. Bramanti, M. Musso, M. Farina, M. Martino, M. Novo, G. Grillo, F. Patriarca, G. Zacchi, M. Krampera, M. Pennisi, E. Galli, M. Martelli, A.J.M. Ferreri, S. Ferrari, R. Saccardi, A. Bermema, A. Guidetti, R. Miceli, P.L. Zinzani, P. Corradini
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
2023 T.J. Phillips, A. Avigdor, R. Gurion, C. Patti, P. Corradini, M. Tani, A. Mehta, I.S. Lossos, P.L. Zinzani, C. Thieblemont, W. Jurczak, F. Zheng, E. Rappold, W. Zhao, P. Jiang, P.W.M. Johnson
Towards a personalized preventive strategy of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an ad hoc Italian expert panel
2023 C. Girmenia, F. Ciceri, P. Corradini, A. Cuneo, F. D'Ancona, P. Musto, A.M. Risitano, M.T. Voso, A. Venditti, G. Barosi
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy
2023 A. Guidetti, A. Dodero, A. Lorenzoni, S. Pizzamiglio, G. Argiroffi, A. Chiappella, F. Bagnoli, V. Marasco, C. Carniti, C. Monfrini, E. Seregni, M. Pennisi, P. Verderio, A. Alessi, P. Corradini
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort
2023 M. Merli, I. Ferrarini, F. Merli, A. Busca, R. Mina, B. Falini, R. Bruna, R. Cairoli, M. Marchetti, A. Romano, M. Cavo, L. Arcaini, L. Trentin, C. Cattaneo, E. Derenzini, N.S. Fracchiolla, F. Marchesi, A. Scattolin, A. Billio, M. Bocchia, M. Massaia, C. Gambacorti-Passerini, F.R. Mauro, M. Gentile, S. Mohamed, M.G. Della Porta, E. Coviello, D. Cilloni, G. Visani, A.B. Federici, M.C. Tisi, L. Cudillo, S. Galimberti, F. Gherlinzoni, L. Pagano, A. Guidetti, L. Bertù, P. Corradini, F. Passamonti, C. Visco
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia
2023 E. Tiacci, A. Mancini, M. Marchetti, G.M. D'Elia, A. Candoni, A. Morotti, A. Romano, A. Gozzetti, A. Broccoli, L. De Carolis, R. Bruna, M.C. Tisi, C. Selleri, M. Capponi, D. Vallisa, C. Cattaneo, M.G. Della Porta, A. Busca, B. Falini, M. Massaia, L. Bertù, A. Pulsoni, P. Rivela, P. Corradini, F. Passamonti
COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)
2023 F. Marchesi, J. Salmanton-García, Z. Emarah, K. Piukovics, M. Nucci, A. López-García, Z. Ráčil, F. Farina, M. Popova, S. Zompi, E. Audisio, M. Ledoux, L. Verga, B. Weinbergerová, T. Szotkovski, M.G. Da Silva, N. Fracchiolla, N. De Jonge, G. Collins, M. Marchetti, G. Magliano, C. García-Vidal, M.M. Biernat, J. Van Doesum, M. Machado, F. Demirkan, M. Al-Khabori, P. Žák, B. Víšek, I. Stoma, G. Méndez, J. Maertens, N. Khanna, I. Espigado, G. Dragonetti, L. Fianchi, M.I. Del Principe, A. Cabirta, I. Ormazabal-Vélez, O. Jaksic, C. Buquicchio, V. Bonuomo, J. Batinić, A.S. Omrani, S. Lamure, O. Finizio, N. Fernández, I. Falces-Romero, O. Blennow, R. Bergantim, N. Ali, S. Win, J. Van Praet, M.C. Tisi, A. Shirinova, M. Schönlein, J. Prattes, M. Piedimonte, V. Petzer, M. Navrátil, A. Kulasekararaj, P. Jindra, J. Sramek, A. Glenthøj, R. Fazzi, C. De Ramón-Sánchez, C. Cattaneo, M. Calbacho, N.C. Bahr, S. El-Ashwah, R. Cordoba, M. Hanakova, G. Zambrotta, M. Sciumè, S. Booth, R.N. Rodrigues, M.V. Sacchi, N. García-Poutón, J. Martín-González, S. Khostelidi, S. Gräfe, L. Rahimli, E. Ammatuna, A. Busca, P. Corradini, M. Hoenigl, N. Klimko, P. Koehler, A. Pagliuca, F. Passamonti, O.A. Cornely, L. Pagano
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study
2023 A. Chiappella, A. Dodero, A. Evangelista, A. Re, L. Orsucci, S.V. Usai, C. Castellino, V. Stefoni, A. Pinto, M. Zanni, R. Ciancia, C. Ghiggi, F.G. Rossi, A. Arcari, F. Ilariucci, V.R. Zilioli, L. Flenghi, M. Celli, S. Volpetti, F. Benedetti, F. Ballerini, G. Musuraca, R. Bruna, C. Patti, F. Leonardi, L. Arcaini, M. Magagnoli, F. Cavallo, A. Bermema, A. Tucci, C. Boccomini, G. Ciccone, C. Carniti, S.A. Pileri, P. Corradini
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas
2023 A. Dodero, S. Bramanti, M. Di Trani, M. Pennisi, S. Ljevar, A. Chiappella, M. Massimo, A. Guidetti, F. Corrado, P.M. Nierychlewska, A. Di Rocco, D. Lorenzini, R. Daoud, C. De Philippis, A. Santoro, C. Carlo-Stella, P. Corradini
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
2023 K. Rejeski, M. Subklewe, M. Aljurf, E. Bachy, A. Balduzzi, P. Barba, B. Bruno, R. Benjamin, M.G. Carrabba, C. Chabannon, F. Ciceri, P. Corradini, J. Delgado, R. Di Blasi, R. Greco, R. Houot, G. Iacoboni, U. Jäger, M.J. Kersten, S. Mielke, A. Nagler, F. Onida, Z. Peric, C. Roddie, A. Ruggeri, F. Sánchez-Guijo, I. Sánchez-Ortega, D. Schneidawind, M. Schubert, J.A. Snowden, C. Thieblemont, M. Topp, P.L. Zinzani, J.G. Gribben, C. Bonini, A. Sureda, I. Yakoub-Agha
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
2023 F. Stella, V. Marasco, G.V. Levati, A. Guidetti, A. De Filippo, M. Pennisi, C. Vismara, R. Miceli, S. Ljevar, C. Tecchio, N. Mordini, G. Gobbi, L. Saracino, P. Corradini
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach
2023 P. Dreger, P. Corradini, J.G. Gribben, B. Glass, M. Jerkeman, M.J. Kersten, F. Morschhauser, A. Mussetti, A. Viardot, P.L. Zinzani, A. Sureda
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents
2023 R. Mina, M.T. Petrucci, F. Bonello, V. Bongarzoni, R. Saccardi, G. Bertuglia, A. Mengarelli, A. Spadaro, C. Lisi, P. Curci, R.M. Lemoli, S. Ballanti, R. Floris, L. Cupelli, P. Tosi, A. Olivieri, D. Rota-Scalabrini, C. Cangialosi, C. Nozzoli, B. Anaclerico, F. Fazio, B. Bruno, K. Mancuso, P. Corradini, G. Milone, M. Boccadoro
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach
2023 P. Dreger, P. Corradini, J.G. Gribben, B. Glass, M. Jerkeman, M.J. Kersten, F. Morschhauser, A. Mussetti, A. Viardot, P.L. Zinzani, A. Sureda
Haematology and specialist palliative medicine education and training
2023 M. Luppi, E. Bandieri, A. Venditti, P. Corradini
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)
2023 M. Breccia, P.P. Olimpieri, S. Celant, O.M. Olimpieri, F. Pane, A. Iurlo, V. Summa, P. Corradini, P. Russo
Predictors of Unsustained Minimal Residual Disease Negativity in Multiple Myeloma (MM) Patients
2023 M. D'Agostino, G. Bertuglia, D. Rota-Scalabrini, A. Belotti, S. Morè, P. Corradini, S. Oliva, A. Ledda, M. Grasso, V. Pavone, S. Ronconi, I.D. Vincelli, S. Ballanti, C. Velluti, C. Cellini, A. Gozzetti, A.D. Palmas, B. Gamberi, K. Mancuso, L. Paris, R. Zambello, M.T. Petrucci, B. Bruno, P. Musto, F. Gay
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
2022 L.J. Nastoupil, J. Kuruvilla, J.C. Chavez, F. Bijou, T.E. Witzig, A. Santoro, I.W. Flinn, C. Boccomini, V.P. Kenkre, P. Corradini, I. Isufi, D.J. Andorsky, L.M. Klein, D.R. Greenwald, R. Sangha, F. Shen, P. Hagner, Y. Li, J. Dobmeyer, N. Gong, S. Uttamsingh, M. Pourdehnad, V. Ribrag
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
2022 V. Ribrag, J.C. Chavez, C. Boccomini, J. Kaplan, J.C. Chandler, A. Santoro, P. Corradini, I.W. Flinn, R. Advani, P.A. Cassier, R. Sangha, V.P. Kenkre, I. Isufi, S. Uttamsingh, P.R. Hagner, A.K. Gandhi, F. Shen, S. Michelliza, H. Haeske, K. Hege, M. Pourdehnad, J. Kuruvilla
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study
2022 M. Petrini, G. Gaidano, A. Mengarelli, U. Consoli, A. Santoro, A.M. Liberati, M. Ladetto, V. Fraticelli, A. Guarini, D. Mannina, P. Ferrando, P. Corradini, P. Musto, C. Stelitano, D. Marino, A. Camera, M. Murineddu, R. Battistini, G. Caparrotti, M. Turrini, L. Arcaini, S. Santini, M. Cerqueti, A.J.M. Ferreri, N. Cantore, A. Inzoli, G. Cardinale, B. Ronci, G. La Nasa, S. Massimi, G. Gaglione, V. Barbiero, M. Martelli